Gillian Ellison

Publications by Year

Research Areas

Melanoma and MAPK Pathways, Protein Degradation and Inhibitors, Computational Drug Discovery Methods, Synthesis and biological activity, Advanced Breast Cancer Therapies

Most-Cited Works

• → Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung Cancer(2006)702 cited
• → EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples(2012)297 cited
• → Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)(2010)261 cited
• → Further evidence to support the melanocytic origin of MDA-MB-435(2002)165 cited
• → A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples(2010)152 cited
• → The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: comparison of methodologies(2013)148 cited
• → The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients(2017)119 cited
• → Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray(2001)116 cited
• → Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study(2009)100 cited
• → Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients(2017)92 cited